Programmed Cell Death Protein 1 (PD-1) is an immune checkpoint receptor expressed on T cells that plays a crucial role in downregulating immune responses and promoting self-tolerance by preventing the activation of T-cells. In cancer therapy, blocking PD-1 with monoclonal antibodies can enhance the immune system's ability to attack tumor cells, making it a significant target in immunotherapy treatments.